Dipyaman Ganguly - Revision history

Tyrone73H144: enhanced formatting per standard format and updated info

2026-03-20T22:09:07Z

enhanced formatting per standard format and updated info

CleanupBot II: Removed empty portal template using script

2023-08-13T23:01:02Z

Removed empty portal template using script

← Older revision		Revision as of 04:31, 14 August 2023
Line 52:		Line 52:
	* [[Dendritic cell]]		* [[Dendritic cell]]
	{{div col end}}		{{div col end}}
	~~{{Portal\|India\|Biology\|Biography}}~~

	== Notes ==		== Notes ==

WikiDwarf: Deprecated parameter removal from Template:infobox scientist

2023-02-16T19:09:12Z

Deprecated parameter removal from Template:infobox scientist

← Older revision		Revision as of 00:39, 17 February 2023
Line 1:		Line 1:
	{{Use dmy dates\|date=February 2020}}		{{Use dmy dates\|date=February 2020}}
	{{Infobox scientist		{{Infobox scientist
	\| name = Dipyaman Ganguly		\| name = Dipyaman Ganguly
	\| image =		\| image =
	\| alt =		\| alt =
	\| caption =		\| caption =
	\| birth_date = 25 October		\| birth_date = 25 October
	\| birth_place = [[Baharampur]], [[West Bengal]], India		\| birth_place = [[Baharampur]], [[West Bengal]], India
	\| death_date =		\| death_date =
	\| death_place =		\| death_place =
	~~\| residence = [[Kolkata]], West Bengal, India~~		\| nationality = [[Indian nationality\|Indian]]
	\| nationality = [[Indian nationality\|Indian]]		\| fields = {{ublist\| [[Immunology]] \| [[Cell biology]] \|}}
	\| fields = {{ublist\| [[Immunology]] \| [[Cell biology]] \|}}		\| workplaces = {{ublist \| [[Indian Institute of Chemical Biology]] }}
	\| workplaces = {{ublist \| [[Indian Institute of Chemical Biology]] }}		\| alma_mater = {{ublist\|[[Rahara Ramakrishna Mission Boys' Home High School\|Rahara Ramakrishna Mission Boys’ Home High School]]\|[[Medical College and Hospital, Kolkata]] \|[[Indian Institute of Chemical Biology]] \| [[University of Texas MD Anderson Cancer Center]] \| [[Columbia University Medical Center]] }}
	\| alma_mater = {{ublist\|[[Rahara Ramakrishna Mission Boys' Home High School\|Rahara Ramakrishna Mission Boys’ Home High School]]\|[[Medical College and Hospital, Kolkata]] \|[[Indian Institute of Chemical Biology]] \| [[University of Texas MD Anderson Cancer Center]] \| [[Columbia University Medical Center]] }}		\| doctoral_advisor =
	\| doctoral_advisor =
	\| doctoral_students =		\| doctoral_students =
	\| known_for = Studies on [[Immunology\|Human Immunology]]		\| known_for = Studies on [[Immunology\|Human Immunology]]
	\| awards = {{ublist\| 2013 [[Ramanujan Fellowship]] \|2017 [[Swarnajayanti Fellowship]] \| 2017 [[National Academy of Sciences, India\|NASI]]-Scopus Young Scientist Award \| 2017/18 [[National Bioscience Award for Career Development\|N-BIOS Prize]] \| 2019 [[CDRI Award for Excellence in Drug Research]]\| 2019 [[Merck Young Scientist Award]] }}		\| awards = {{ublist\| 2013 [[Ramanujan Fellowship]] \|2017 [[Swarnajayanti Fellowship]] \| 2017 [[National Academy of Sciences, India\|NASI]]-Scopus Young Scientist Award \| 2017/18 [[National Bioscience Award for Career Development\|N-BIOS Prize]] \| 2019 [[CDRI Award for Excellence in Drug Research]]\| 2019 [[Merck Young Scientist Award]] }}
	}}		}}
	'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web \|url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf \|title=Profile on SERB \|date=2018-12-27 \|website=Scientific and Engineering Research Board \|access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web \|url=https://sites.google.com/site/dclabiicb/dclab-team \|title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab \|date=2018-12-27 \|website=sites.google.com \|access-date=2018-12-27}}</ref>		'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web \|url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf \|title=Profile on SERB \|date=2018-12-27 \|website=Scientific and Engineering Research Board \|access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web \|url=https://sites.google.com/site/dclabiicb/dclab-team \|title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab \|date=2018-12-27 \|website=sites.google.com \|access-date=2018-12-27}}</ref>
Line 24:		Line 23:

	== Scientific contribution ==		== Scientific contribution ==
	Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal\|last1=Liu\|first1=Chinky Shiu Chen\|last2=Raychaudhuri\|first2=Deblina\|last3=Paul\|first3=Barnali\|last4=Chakrabarty\|first4=Yogaditya\|last5=Ghosh\|first5=Amrit Raj\|last6=Rahaman\|first6=Oindrila\|last7=Talukdar\|first7=Arindam\|last8=Ganguly\|first8=Dipyaman\|date=2018-02-15\|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation\|journal=The Journal of Immunology\|language=en\|volume=200\|issue=4\|pages=1255–1260\|doi=10.4049/jimmunol.1701118\|pmid=29330322\|issn=0022-1767\|doi-access=free}}</ref> They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web\|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/\|title=Why the obese are prone to diabetes: a protein gives a clue\|date=2016-09-26\|website=The Indian Express\|language=en-IN\|access-date=2019-07-10}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526\|title=Obesity link to diabetes decoded\|website=www.telegraphindia.com\|language=en\|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal\|last1=Ganguly\|first1=Dipyaman\|last2=Chamilos\|first2=Georgios\|last3=Lande\|first3=Roberto\|last4=Gregorio\|first4=Josh\|last5=Meller\|first5=Stephan\|last6=Facchinetti\|first6=Valeria\|last7=Homey\|first7=Bernhard\|last8=Barrat\|first8=Franck J.\|last9=Zal\|first9=Tomasz\|date=2009-08-31\|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8\|journal=The Journal of Experimental Medicine\|language=en\|volume=206\|issue=9\|pages=1983–1994\|doi=10.1084/jem.20090480\|pmid=19703986\|issn=0022-1007\|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal\|last=Bosch\|first=Xavier\|date=2011-08-25\|title=Systemic Lupus Erythematosus and the Neutrophil\|journal=New England Journal of Medicine\|language=en\|volume=365\|issue=8\|pages=758–760\|doi=10.1056/NEJMcibr1107085\|pmid=21864171\|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web\|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/\|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases\|date=2018-06-03\|website=BioTech Times\|language=en-US\|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite ~~document~~\|url=https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1/\|title=Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomized control trial\|year=2020\|doi=10.1101/2020.11.25.20237883\|last1=Ray\|first1=Yogiraj\|last2=Paul\|first2=Shekhar Ranjan\|last3=Bandopadhyay\|first3=Purbita\|last4=d'Rozario\|first4=Ranit\|last5=Sarif\|first5=Jafar\|last6=Lahiri\|first6=Abhishake\|last7=Bhowmik\|first7=Debaleena\|last8=Vasudevan\|first8=Janani Srinivasa\|last9=Maurya\|first9=Ranjeet\|last10=Kanakan\|first10=Akshay\|last11=Sharma\|first11=Sachin\|last12=Kumar\|first12=Manish\|last13=Singh\|first13=Praveen\|last14=Roy\|first14=Rammohan\|last15=Chaudhury\|first15=Kausik\|last16=Maiti\|first16=Rajsekhar\|last17=Bagchi\|first17=Saugata\|last18=Maiti\|first18=Ayan\|last19=Perwez\|first19=Md. Masoom\|last20=Mondal\|first20=Abhinandan\|last21=Tewari\|first21=Avinash\|last22=Mandal\|first22=Samik\|last23=Roy\|first23=Arpan\|last24=Saha\|first24=Moumita\|last25=Biswas\|first25=Durba\|last26=Maiti\|first26=Chikam\|last27=Chakraborty\|first27=Sayantan\|last28=Sarkar\|first28=Biswanath Sharma\|last29=Haldar\|first29=Anima\|last30=Saha\|first30=Bibhuti\|s2cid=227189790\|display-authors=1}}</ref>		Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal\|last1=Liu\|first1=Chinky Shiu Chen\|last2=Raychaudhuri\|first2=Deblina\|last3=Paul\|first3=Barnali\|last4=Chakrabarty\|first4=Yogaditya\|last5=Ghosh\|first5=Amrit Raj\|last6=Rahaman\|first6=Oindrila\|last7=Talukdar\|first7=Arindam\|last8=Ganguly\|first8=Dipyaman\|date=2018-02-15\|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation\|journal=The Journal of Immunology\|language=en\|volume=200\|issue=4\|pages=1255–1260\|doi=10.4049/jimmunol.1701118\|pmid=29330322\|issn=0022-1767\|doi-access=free}}</ref> They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web\|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/\|title=Why the obese are prone to diabetes: a protein gives a clue\|date=2016-09-26\|website=The Indian Express\|language=en-IN\|access-date=2019-07-10}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526\|title=Obesity link to diabetes decoded\|website=www.telegraphindia.com\|language=en\|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal\|last1=Ganguly\|first1=Dipyaman\|last2=Chamilos\|first2=Georgios\|last3=Lande\|first3=Roberto\|last4=Gregorio\|first4=Josh\|last5=Meller\|first5=Stephan\|last6=Facchinetti\|first6=Valeria\|last7=Homey\|first7=Bernhard\|last8=Barrat\|first8=Franck J.\|last9=Zal\|first9=Tomasz\|date=2009-08-31\|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8\|journal=The Journal of Experimental Medicine\|language=en\|volume=206\|issue=9\|pages=1983–1994\|doi=10.1084/jem.20090480\|pmid=19703986\|issn=0022-1007\|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal\|last=Bosch\|first=Xavier\|date=2011-08-25\|title=Systemic Lupus Erythematosus and the Neutrophil\|journal=New England Journal of Medicine\|language=en\|volume=365\|issue=8\|pages=758–760\|doi=10.1056/NEJMcibr1107085\|pmid=21864171\|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web\|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/\|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases\|date=2018-06-03\|website=BioTech Times\|language=en-US\|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite journal\|url=https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1/\|title=Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomized control trial\|year=2020\|doi=10.1101/2020.11.25.20237883\|last1=Ray\|first1=Yogiraj\|last2=Paul\|first2=Shekhar Ranjan\|last3=Bandopadhyay\|first3=Purbita\|last4=d'Rozario\|first4=Ranit\|last5=Sarif\|first5=Jafar\|last6=Lahiri\|first6=Abhishake\|last7=Bhowmik\|first7=Debaleena\|last8=Vasudevan\|first8=Janani Srinivasa\|last9=Maurya\|first9=Ranjeet\|last10=Kanakan\|first10=Akshay\|last11=Sharma\|first11=Sachin\|last12=Kumar\|first12=Manish\|last13=Singh\|first13=Praveen\|last14=Roy\|first14=Rammohan\|last15=Chaudhury\|first15=Kausik\|last16=Maiti\|first16=Rajsekhar\|last17=Bagchi\|first17=Saugata\|last18=Maiti\|first18=Ayan\|last19=Perwez\|first19=Md. Masoom\|last20=Mondal\|first20=Abhinandan\|last21=Tewari\|first21=Avinash\|last22=Mandal\|first22=Samik\|last23=Roy\|first23=Arpan\|last24=Saha\|first24=Moumita\|last25=Biswas\|first25=Durba\|last26=Maiti\|first26=Chikam\|last27=Chakraborty\|first27=Sayantan\|last28=Sarkar\|first28=Biswanath Sharma\|last29=Haldar\|first29=Anima\|last30=Saha\|first30=Bibhuti\|s2cid=227189790\|display-authors=1}}</ref>

	== Awards ==		== Awards ==
Line 30:		Line 29:

	== Public outreach ==		== Public outreach ==
	Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web\|url=http://dialogue.ias.ac.in/\|title=DIALOGUE - Science, Scientists, and Society\|website=Dialogue\|access-date=2019-07-10}}</ref><ref>{{Cite web\|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs\|title=Are we reaching the 'public' with our public outreach programs?\|date=2018-07-13\|website=IndiaBioscience\|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health. <ref>{{Cite web\|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874\|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372\|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550\|title=One pandemic unmasking another}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558\|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web\|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece\|title=More 'strain' on Covid management}}</ref><ref>{{Cite web\|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece\|title=Slow mutation of the Covid pandemic}}</ref><ref>{{Cite web\|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html\|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web\|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html\|title=Herd immunity may come before COVID-19 vaccine}}</ref>		Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web\|url=http://dialogue.ias.ac.in/\|title=DIALOGUE - Science, Scientists, and Society\|website=Dialogue\|access-date=2019-07-10}}</ref><ref>{{Cite web\|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs\|title=Are we reaching the 'public' with our public outreach programs?\|date=2018-07-13\|website=IndiaBioscience\|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health.<ref>{{Cite web\|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874\|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372\|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550\|title=One pandemic unmasking another}}</ref><ref>{{Cite web\|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558\|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web\|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece\|title=More 'strain' on Covid management\|date=12 January 2021 }}</ref><ref>{{Cite web\|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece\|title=Slow mutation of the Covid pandemic\|date=9 February 2021 }}</ref><ref>{{Cite web\|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html\|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web\|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html\|title=Herd immunity may come before COVID-19 vaccine}}</ref>

	== Selected bibliography ==		== Selected bibliography ==
Line 45:		Line 44:
	* {{cite journal\|vauthors=Ganguly D, Haak S, Sisirak V, Reizis B\|title=The role of dendritic cells in autoimmunity\|journal=Nature Reviews Immunology\|volume=13\|pages=566–577\|date=Aug 2013\|issue=8\|pmid=23827956 \|doi=10.1038/nri3477\|pmc=4160805}}		* {{cite journal\|vauthors=Ganguly D, Haak S, Sisirak V, Reizis B\|title=The role of dendritic cells in autoimmunity\|journal=Nature Reviews Immunology\|volume=13\|pages=566–577\|date=Aug 2013\|issue=8\|pmid=23827956 \|doi=10.1038/nri3477\|pmc=4160805}}
	* {{cite journal\|vauthors=Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M\|title=Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8\|journal=The Journal of Experimental Medicine\|volume=206\|pages=1983–1994\|date=Aug 2009\|issue=9\|pmid=19703986 \|doi=10.1084/jem.20090480\|pmc=2737167\|doi-access=free}}		* {{cite journal\|vauthors=Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M\|title=Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8\|journal=The Journal of Experimental Medicine\|volume=206\|pages=1983–1994\|date=Aug 2009\|issue=9\|pmid=19703986 \|doi=10.1084/jem.20090480\|pmc=2737167\|doi-access=free}}
	* {{cite journal\|vauthors=Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A\|title=A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist\|journal=Journal of Medicinal Chemistry\|volume=63\|pages=4776–4789\|date=May 2020\|issue=9\|pmid=32302115 \|doi=10.1021/acs.jmedchem.0c00011}}		* {{cite journal\|vauthors=Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A\|title=A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist\|journal=Journal of Medicinal Chemistry\|volume=63\|pages=4776–4789\|date=May 2020\|issue=9\|pmid=32302115 \|doi=10.1021/acs.jmedchem.0c00011\|s2cid=215809717 }}
	{{Refend}}		{{Refend}}

Line 65:		Line 64:

	{{N-BIOS Laureates 2010–2019}}		{{N-BIOS Laureates 2010–2019}}

	~~{{authority control}}~~

	{{DEFAULTSORT:Ganguly, Dipyaman}}		{{DEFAULTSORT:Ganguly, Dipyaman}}
Line 79:		Line 76:
	[[Category:Indian immunologists]]		[[Category:Indian immunologists]]
	[[Category:Living people]]		[[Category:Living people]]
			[[Category:Scientists from West Bengal]]

UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

2021-07-23T09:52:19Z

robot: Update article (please report if you notice any mistake or error in this edit)

← Older revision	Revision as of 15:22, 23 July 2021
(No difference)

>Citation bot: Alter: template type. Add: display-authors, s2cid, year, authors 1-30. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_toolbar

2021-06-13T13:03:23Z

Alter: template type. Add: display-authors, s2cid, year, authors 1-30. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_toolbar

New page

{{Use dmy dates|date=February 2020}}
{{Infobox scientist
| name = Dipyaman Ganguly
| image =
| alt =
| caption =
| birth_date = 25 October
| birth_place = [[Baharampur]], [[West Bengal]], India
| death_date =
| death_place =
| residence = [[Kolkata]], West Bengal, India
| nationality = [[Indian nationality|Indian]]
| fields = {{ublist| [[Immunology]] | [[Cell biology]] |}}
| workplaces = {{ublist | [[Indian Institute of Chemical Biology]] }}
| alma_mater = {{ublist|[[Rahara Ramakrishna Mission Boys' Home High School|Rahara Ramakrishna Mission Boys’ Home High School]]|[[Medical College and Hospital, Kolkata]] |[[Indian Institute of Chemical Biology]] | [[University of Texas MD Anderson Cancer Center]] | [[Columbia University Medical Center]] }}
| doctoral_advisor =
| doctoral_students =
| known_for = Studies on [[Immunology|Human Immunology]]
| awards = {{ublist| 2013 [[Ramanujan Fellowship]] |2017 [[Swarnajayanti Fellowship]] | 2017 [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award | 2017/18 [[National Bioscience Award for Career Development|N-BIOS Prize]] | 2019 [[CDRI Award for Excellence in Drug Research]]| 2019 [[Merck Young Scientist Award]] }}
}}
'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web |url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf |title=Profile on SERB |date=2018-12-27 |website=Scientific and Engineering Research Board |access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web |url=https://sites.google.com/site/dclabiicb/dclab-team |title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab |date=2018-12-27 |website=sites.google.com |access-date=2018-12-27}}</ref>

Ganguly graduated in medicine from [[Medical College and Hospital, Kolkata]] in 2001 but shifted his focus to biomedical research and joined the [[Institute of Genomics and Integrative Biology]] as a clinical associate.<ref name="Profile on SERB" /> In 2003, he joined [[Indian Institute of Chemical Biology]] for doctoral research as a research scholar which earned him his first PhD in 2006. Moving to the US, he carried on his research at [[University of Texas MD Anderson Cancer Center]] and received another PhD from the [[University of Texas Health Science Center at Houston]].<ref name="IICB profile">{{Cite web |url=http://iicb.res.in/dipyaman-ganguly/ |title=IICB profile |date=2018-12-27 |website=Indian Institute of Chemical Biology |language=en-US |access-date=2018-12-27}}</ref> His post-doctoral work was at the [[Columbia University Medical Center]] as an SLE Foundation Fellow<ref>{{Cite web|url=http://www.eurekalert.org/pub_releases/2011-04/lri-slf040511.php|title=S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research|website=EurekAlert!|language=en|access-date=2019-07-10}}</ref> and on his return to India, he joined IICB where he is a Principal Scientist. He is also a Swarnajayanti Fellow of the [[Department of Science and Technology (India)|Department of Science and Technology]], and was formerly a Ramanujan Fellow of the [[Science and Engineering Research Board]] of the [[Department of Science and Technology (India)|Department of Science and Technology]].

== Scientific contribution ==
Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal|last1=Liu|first1=Chinky Shiu Chen|last2=Raychaudhuri|first2=Deblina|last3=Paul|first3=Barnali|last4=Chakrabarty|first4=Yogaditya|last5=Ghosh|first5=Amrit Raj|last6=Rahaman|first6=Oindrila|last7=Talukdar|first7=Arindam|last8=Ganguly|first8=Dipyaman|date=2018-02-15|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=The Journal of Immunology|language=en|volume=200|issue=4|pages=1255–1260|doi=10.4049/jimmunol.1701118|pmid=29330322|issn=0022-1767|doi-access=free}}</ref> They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/|title=Why the obese are prone to diabetes: a protein gives a clue|date=2016-09-26|website=The Indian Express|language=en-IN|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526|title=Obesity link to diabetes decoded|website=www.telegraphindia.com|language=en|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal|last1=Ganguly|first1=Dipyaman|last2=Chamilos|first2=Georgios|last3=Lande|first3=Roberto|last4=Gregorio|first4=Josh|last5=Meller|first5=Stephan|last6=Facchinetti|first6=Valeria|last7=Homey|first7=Bernhard|last8=Barrat|first8=Franck J.|last9=Zal|first9=Tomasz|date=2009-08-31|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|language=en|volume=206|issue=9|pages=1983–1994|doi=10.1084/jem.20090480|pmid=19703986|issn=0022-1007|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal|last=Bosch|first=Xavier|date=2011-08-25|title=Systemic Lupus Erythematosus and the Neutrophil|journal=New England Journal of Medicine|language=en|volume=365|issue=8|pages=758–760|doi=10.1056/NEJMcibr1107085|pmid=21864171|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases|date=2018-06-03|website=BioTech Times|language=en-US|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite document|url=https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1/|title=Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomized control trial|year=2020|doi=10.1101/2020.11.25.20237883|last1=Ray|first1=Yogiraj|last2=Paul|first2=Shekhar Ranjan|last3=Bandopadhyay|first3=Purbita|last4=d'Rozario|first4=Ranit|last5=Sarif|first5=Jafar|last6=Lahiri|first6=Abhishake|last7=Bhowmik|first7=Debaleena|last8=Vasudevan|first8=Janani Srinivasa|last9=Maurya|first9=Ranjeet|last10=Kanakan|first10=Akshay|last11=Sharma|first11=Sachin|last12=Kumar|first12=Manish|last13=Singh|first13=Praveen|last14=Roy|first14=Rammohan|last15=Chaudhury|first15=Kausik|last16=Maiti|first16=Rajsekhar|last17=Bagchi|first17=Saugata|last18=Maiti|first18=Ayan|last19=Perwez|first19=Md. Masoom|last20=Mondal|first20=Abhinandan|last21=Tewari|first21=Avinash|last22=Mandal|first22=Samik|last23=Roy|first23=Arpan|last24=Saha|first24=Moumita|last25=Biswas|first25=Durba|last26=Maiti|first26=Chikam|last27=Chakraborty|first27=Sayantan|last28=Sarkar|first28=Biswanath Sharma|last29=Haldar|first29=Anima|last30=Saha|first30=Bibhuti|s2cid=227189790|display-authors=1}}</ref>

== Awards ==
The [[Department of Biotechnology]] of the Government of India awarded him the [[National Bioscience Award for Career Development]], one of the highest Indian science awards, for his contributions to biosciences, in 2017/18.<ref name="Awardees of National Bioscience Awards for Career Development">{{Cite web |url=http://dbtindia.nic.in/wp-content/uploads/2014/03/list_of_bioscience_awardees.pdf |title=Awardees of National Bioscience Awards for Career Development |date=2016 |publisher=Department of Biotechnology |access-date=2017-11-20}}</ref> He is also a recipient of the Merck Young Scientist Award, the CDRI Award for Excellence in Drug Research from CSIR-[[Central Drug Research Institute]], Swarnajayanthi Fellowship of the [[Department of Science and Technology (India)|Department of Science and Technology]] and the [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award of the [[Elsevier]].<ref name="Scopus Award 2017">{{Cite web |url=http://southasia.elsevier.com/ElsevierDNN/ScopusAward2017/tabid/3051/Default.aspx |title=Scopus Award 2017 |date=2018-12-27 |website=southasia.elsevier.com |access-date=2018-12-27}}</ref>

== Public outreach ==
Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web|url=http://dialogue.ias.ac.in/|title=DIALOGUE - Science, Scientists, and Society|website=Dialogue|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs|title=Are we reaching the 'public' with our public outreach programs?|date=2018-07-13|website=IndiaBioscience|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health. <ref>{{Cite web|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550|title=One pandemic unmasking another}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece|title=More 'strain' on Covid management}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece|title=Slow mutation of the Covid pandemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html|title=Herd immunity may come before COVID-19 vaccine}}</ref>

== Selected bibliography ==
{{refbegin|2}}
* {{cite journal|vauthors=Sisirak V, Ganguly D, Lewis KL, Couillault C, Tanaka L, Bolland S, D'Agati V, Elkon KB, Reizis B|title=Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus|journal=The Journal of Experimental Medicine|volume=211|issue=10|pages=1969–76|date=September 2014|pmid=25180061|pmc=4172218|doi=10.1084/jem.20132522}}
* {{cite journal|vauthors=Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M|title=Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus|journal=Science Translational Medicine|volume=3|issue=73|pages=73ra19|date=March 2011|pmid=21389263|pmc=3399524|doi=10.1126/scitranslmed.3001180}}
* {{cite journal|vauthors=Rahaman O, Bhattacharya R, Liu C, Raychaudhuri D, Ghosh AR, Bandopadhyay P, Pal S, Goswami RP, Sircar G, Ghosh P, Ganguly D|title=Cutting Edge: Dysregulated Endocannabinoid-Rheostat for Plasmacytoid Dendritic Cell Activation in a Systemic Lupus Endophenotype|journal=Journal of Immunology|volume=202|pages=1674–1679|date=March 2019|issue=6|pmid=30728209|doi=10.4049/jimmunol.1801521|doi-access=free}}
* {{cite journal|vauthors=Liu C, Raychaudhuri D, Paul B, Chakrabarty Y, Ghosh AR, Rahaman O, Talukdar A, Ganguly D|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=Journal of Immunology|volume=200|pages=1255–1260|date=Feb 2018|issue=4|pmid=29330322|doi=10.4049/jimmunol.1701118|doi-access=free}}
* {{cite journal|vauthors=Ganguly D|title=Do Type I Interferons Link Systemic Autoimmunities and Metabolic Syndrome in a Pathogenetic Continuum?
|journal=Trends in Immunology|volume=39|pages=28–43|date=Jan 2018|issue=1
|pmid=28826817|doi=10.1016/j.it.2017.07.001}}
* {{cite journal|vauthors=Ghosh AR, Bhattacharya R, Bhattacharya S, Nargis T, Rahaman O, Duttagupta P, Raychaudhuri D, Liu CS, Roy S, Ghosh P, Khanna S, Chaudhuri T, Tantia O, Haak S, Bandyopadhyay S, Mukhopadhyay S, Chakrabarti P, Ganguly D|title=Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation|journal=Diabetes|volume=65|pages=3440–3452|date=Nov 2016|issue=11|pmid=27561727 |doi=10.2337/db16-0331|doi-access=free}}
* {{cite journal|vauthors=Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T, Ladbury JE, Homey B, Watowich S, Modlin RL, Kontoyiannis DP, Liu YJ, Arold ST, Gilliet M|title=T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26|journal=Nature Immunology|volume=16|pages=970–979|date=Sep 2015|issue=9|pmid=26168081 |doi=10.1038/ni.3211|pmc=4776746}}
* {{cite journal|vauthors=Ganguly D, Haak S, Sisirak V, Reizis B|title=The role of dendritic cells in autoimmunity|journal=Nature Reviews Immunology|volume=13|pages=566–577|date=Aug 2013|issue=8|pmid=23827956 |doi=10.1038/nri3477|pmc=4160805}}
* {{cite journal|vauthors=Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M|title=Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|volume=206|pages=1983–1994|date=Aug 2009|issue=9|pmid=19703986 |doi=10.1084/jem.20090480|pmc=2737167|doi-access=free}}
* {{cite journal|vauthors=Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A|title=A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist|journal=Journal of Medicinal Chemistry|volume=63|pages=4776–4789|date=May 2020|issue=9|pmid=32302115 |doi=10.1021/acs.jmedchem.0c00011}}
{{Refend}}

== See also ==
{{Div col|colwidth=30em}}
* [[T helper 17 cell]]
* [[Dendritic cell]]
{{div col end}}
{{Portal|India|Biology|Biography}}

== Notes ==
{{reflist|group=note|2}}

== References ==
{{reflist}}

== External links ==
* {{Cite web |url=https://www.pubfacts.com/author/Dipyaman+Ganguly |title=Publications Authored by Dipyaman Ganguly |date=2018-12-27 |website=PubFacts |access-date=2018-12-27}}

{{N-BIOS Laureates 2010–2019}}

{{authority control}}

{{DEFAULTSORT:Ganguly, Dipyaman}}
[[Category:Indian scientific authors]]
[[Category:Year of birth missing (living people)]]
[[Category:N-BIOS Prize recipients]]
[[Category:Indian cell biologists]]
[[Category:Medical College and Hospital, Kolkata alumni]]
[[Category:Maulana Abul Kalam Azad University of Technology]]
[[Category:University of Texas MD Anderson Cancer Center alumni]]
[[Category:Columbia University alumni]]
[[Category:Indian immunologists]]
[[Category:Living people]]